Monetization
The pricing model and the liability math that anchors it.
The model, not proof. Pricing and penetration here are assumptions, not validated by paying customers. Frame them as the hypothesis.
The pricing logic
Conclave is priced against liability avoided, not against notetaker commodity pricing. For a regulated team, the relevant comparison isn't "$10/seat like Otter" — it's the cost of the breach or consent violation the product is designed to prevent.
- Assumed list: ~$600–1,200 / seat / year.
- Against the downside, that's a rounding error.
The liability math
- Average healthcare data breach: ~$9.77M.
- Largest BIPA settlement: $650M (Facebook, biometric/voiceprint consent).
A tool that keeps voiceprints consented and keeps content operator-blind is cheap insurance against numbers like these — which is the entire pricing argument.
Why the wedge converts
The near-term motion targets buyers who can say yes without procurement: privacy-native startups and regulated boutiques where a partner swipes a card. That's what makes a modeled ~$20–50M ARR from under 2% of seats plausible on paper — small penetration of a compliance-driven market, not a land grab.
See Market for sizing and Competitive landscape for why incumbents can't simply copy the posture.
Source: pitching/Conclave-Market-Monetization-Memo.md.